Clusterin pharmaceuticals and treatment methods using the same
Disclosed are pharmaceutical compositions comprising clusterin and polypeptides substantially the same as clusterin and treatment methods for inflammatory diseases and dry eye disease. The pharmaceutical compositions include an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The clusterin is preferably secreted clusterin. The method of treating dry eye disease includes administering to a patient in need an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated polypeptide substantially the same as clusterin. The method of treating a disease state characterized by inflammation includes administering to a patient having the disease state an amount of isolated clusterin or a protein substantially the same as clusterin effective to decrease the activity of a matrix metallproteinase selected from the group consisting of MMP-9, MMP-2 and MMP-7.
1. A method of treating dry eye disease comprising:
administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising an isolated clusterin or an isolated fragment of clusterin, wherein said clusterin or said fragment of clusterin binds and reduces the activity of at least one of MMP-9, MMP-2, or MMP-7.
2. The method of claim 1 , wherein the pharmaceutical composition comprises secreted clusterin.
3. The method of claim 1 , wherein the administration is topical.
4. The method of claim 1 , wherein the pharmaceutical composition further comprises a liquid carrier, and administration is by contacting the pharmaceutical composition to the surface of an eye of the patient.
5. The method of claim 1 , wherein the pharmaceutical composition further comprises a carrier.
6. The method of claim 1 , wherein the carrier is a sterile solution.